Floatz logo

Kite-363

Chronic Inflammatory Demyelinating Polyneuropathy

Kite, A Gilead CompanyCell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

15 Active assets in the Chronic Inflammatory Demyelinating Polyneuropathy cohort.

Asset / SponsorPhaseRating
AMIFAMPRIDINE
National Center for Research Resources (NCRR)
Phase 3BB
HUMAN IMMUNOGLOBULINS
National Center for Research Resources (NCRR)
Phase 3BB
i10e
Laboratoire français de Fractionnement et de Biotechnologies
Phase 3B
ETOPOSIDE
Fred Hutchinson Cancer Center
Phase 2CCC
CARMUSTINE
Fred Hutchinson Cancer Center
Phase 2CCC

View all 18 →

Same molecule, other indications

Kite-363 is also rated in:

B-cell non-Hodgkin lymphomaDormant
CCC
Indicative ·
48 / 100
View asset →
myasthenia gravisDormant
CC
Indicative ·
43 / 100
View asset →
multiple sclerosisDormant
C
Indicative ·
37 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →